| Post Date: | 10 Oct 2011 |
| Expiry Date: | 04 Oct 2012 |
| CAS No: | 139110-80-8 |
| Detailed Description: | Zanamivir (GMP)
CAS: 139110-80-8 Introduction: Zanamivir ( INN ) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus . Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation. Simcere's Zanamivir API: In 2006 Simcere was granted a license by GlaxoSmithKline to make products containing Zanamivir, Simcere is the only pharmaceutical company in mainland China that has such a license. The API materials and preparations of Zanamivir are both successfully passed and received SFDA GMP certification. Some inspection data Specification CP Properties White or off white crystalline powder Specific rotation +37.7o PH 5.6 Chloride 0.02% max Total bacteria 100 cfu/g max Yeasts and Moulds 10 cfu/g max Escherichia coli Not detected Pseudomonas aeruginosa Not detected Staphylococcus aureus Not detected Assay 98% Min Keyword: Zanamivir, Relenza, Antiviral, Influenza, 139110-80-8 |
| Contact Information | |
|
Please Sign In to view this member's contact information. Not a Vvchem.com member yet? Join Now. Its Free! |
